Headlines about Rosetta Genomics (NASDAQ:ROSG) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rosetta Genomics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.1612619815153 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Rosetta Genomics (NASDAQ ROSG) opened at $0.75 on Tuesday. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.03. Rosetta Genomics has a 12-month low of $0.61 and a 12-month high of $9.72.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Rosetta Genomics (ROSG) Share Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/21/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-rosetta-genomics-rosg-share-price.html.

About Rosetta Genomics

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Insider Buying and Selling by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Receive News & Stock Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related stocks with our FREE daily email newsletter.